Showing results (211-220 of 261) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Blood Advances|June 14, 2018
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCLChelsea C Pinnix, Andrea K Ng, Bouthaina S Dabaja, et al.
Heart (British Cardiac Society)|November 9, 2022
Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancerCho-Han Chiang, Cho-Hung Chiang, Cho-Hsien Chiang, et al.
Blood Advances|September 1, 2019
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and childrenJennifer S Whangbo, Haesook T Kim, Nikola Mirkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaPhilippe Armand, Scott Rodig, Vladimir Melnichenko, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2019
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with NivolumabAiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Pageof 27